Beta-O2 Technologies is a biomedical company developing a proprietary implantable bio-artificial pancreas for the treatment of Type 1 diabetes (T1D). Its product, the ßAir, is a small medical device, implanted in a minimally invasive procedure. The Company's solution provides patients with freedom from injecting insulin and monitoring glucose levels and reduces the risk of diabetes complications and hypoglycemic episodes.